Immunovant, Inc. (IMVT)
Immunovant has a market cap or net worth of $2.69 billion. The enterprise value is $2.32 billion.
The last earnings date was Monday, May 22, 2023, before market open.
|Earnings Date||May 22, 2023|
Immunovant has 130.41 million shares outstanding. The number of shares has increased by 12.21% in one year.
|Shares Change (YoY)||+12.21%|
|Shares Change (QoQ)||+1.35%|
|Owned by Insiders (%)||58.66%|
|Owned by Institutions (%)||43.88%|
|EV / Earnings||n/a|
|EV / Sales||n/a|
|EV / EBITDA||n/a|
|EV / EBIT||n/a|
|EV / FCF||n/a|
The company has a current ratio of 9.34, with a Debt / Equity ratio of 0.00.
|Debt / Equity||0.00|
|Debt / EBITDA||n/a|
|Debt / FCF||n/a|
Return on equity (ROE) is -52.40%.
|Return on Equity (ROE)||-52.40%|
|Return on Assets (ROA)||-48.30%|
|Return on Capital (ROIC)||n/a|
|Revenue Per Employee||n/a|
|Profits Per Employee||-$1.29M|
In the past 12 months, Immunovant has paid $9,000 in taxes.
|Effective Tax Rate||n/a|
Stock Price Statistics
The stock price has increased by +403.16% in the last 52 weeks. The beta is 1.02, so Immunovant's price volatility has been similar to the market average.
|52-Week Price Change||+403.16%|
|50-Day Moving Average||17.46|
|200-Day Moving Average||13.96|
|Average Volume (30 Days)||1,012,528|
Short Selling Information
The latest short interest is 4.31 million, so 3.30% of the outstanding shares have been sold short.
|Short Previous Month||4.53M|
|Short % of Shares Out||3.30%|
|Short % of Float||8.89%|
|Short Ratio (days to cover)||4.97|
|Earnings Per Share (EPS)||-$1.71|
The company has $376.53 million in cash and $1.22 million in debt, giving a net cash position of $375.31 million or $2.88 per share.
|Cash & Cash Equivalents||376.53M|
|Net Cash Per Share||$2.88|
|Equity / Book Value||362.49M|
|Book Value Per Share||2.78|
In the last 12 months, operating cash flow was -$188.19 million and capital expenditures -$197,000, giving a free cash flow of -$188.39 million.
|Operating Cash Flow||-188.19M|
|Free Cash Flow||-188.39M|
|FCF Per Share||-$1.53|
Dividends & Yields
Immunovant does not appear to pay any dividends at this time.
|Dividend Per Share||n/a|
|Dividend Growth (YoY)||n/a|
The average price target for Immunovant is $23.38, which is 13.17% higher than the current price. The consensus rating is "Strong Buy".
|Price Target Difference||13.17%|
|Analyst Consensus||Strong Buy|
|Revenue Growth Forecast (5Y)||n/a|
|EPS Growth Forecast (5Y)||n/a|
This stock does not have any record of stock splits.
|Last Split Date||n/a|